250 related articles for article (PubMed ID: 25733708)
1. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
[TBL] [Abstract][Full Text] [Related]
2. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
3. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
[TBL] [Abstract][Full Text] [Related]
4. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
[TBL] [Abstract][Full Text] [Related]
5. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
Ko AH
Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
[TBL] [Abstract][Full Text] [Related]
7. Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy.
Awasthi N; Schwarz MA; Zhang C; Klinz SG; Meyer-Losic F; Beaufils B; Thiagalingam A; Schwarz RE
Mol Cancer Ther; 2022 Jul; 21(7):1149-1159. PubMed ID: 35500018
[TBL] [Abstract][Full Text] [Related]
8. Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study.
Ramanathan RK; Korn RL; Raghunand N; Sachdev JC; Newbold RG; Jameson G; Fetterly GJ; Prey J; Klinz SG; Kim J; Cain J; Hendriks BS; Drummond DC; Bayever E; Fitzgerald JB
Clin Cancer Res; 2017 Jul; 23(14):3638-3648. PubMed ID: 28159813
[No Abstract] [Full Text] [Related]
9. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
[TBL] [Abstract][Full Text] [Related]
10. Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer.
Smith CJ; Bekaii-Saab TS; Cook KD; Eiring RA; Halfdanarson TR; Hanna M; Jin Z; Jochum JA; Ma WW; Mitchell JL; Pitot HC; Jatoi A
Pancreatology; 2021 Mar; 21(2):379-383. PubMed ID: 33468394
[TBL] [Abstract][Full Text] [Related]
11. Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.
Hare JI; Neijzen RW; Anantha M; Dos Santos N; Harasym N; Webb MS; Allen TM; Bally MB; Waterhouse DN
PLoS One; 2013; 8(4):e62349. PubMed ID: 23626804
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
Noble CO; Krauze MT; Drummond DC; Forsayeth J; Hayes ME; Beyer J; Hadaczek P; Berger MS; Kirpotin DB; Bankiewicz KS; Park JW
Nanomedicine (Lond); 2014 Jul; 9(14):2099-108. PubMed ID: 24494810
[TBL] [Abstract][Full Text] [Related]
13. Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.
May WA; Grigoryan RS; Keshelava N; Cabral DJ; Christensen LL; Jenabi J; Ji L; Triche TJ; Lawlor ER; Reynolds CP
PLoS One; 2013; 8(12):e80060. PubMed ID: 24312454
[TBL] [Abstract][Full Text] [Related]
14. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
Ramsay EC; Anantha M; Zastre J; Meijs M; Zonderhuis J; Strutt D; Webb MS; Waterhouse D; Bally MB
Clin Cancer Res; 2008 Feb; 14(4):1208-17. PubMed ID: 18281556
[TBL] [Abstract][Full Text] [Related]
15. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Woo MH; Peterson JK; Billups C; Liang H; Bjornsti MA; Houghton PJ
Cancer Chemother Pharmacol; 2005 May; 55(5):411-9. PubMed ID: 15503024
[TBL] [Abstract][Full Text] [Related]
17. Polypeptide-based Micelles for Delivery of Irinotecan: Physicochemical and In vivo Characterization.
Ramasamy T; Choi JY; Cho HJ; Umadevi SK; Shin BS; Choi HG; Yong CS; Kim JO
Pharm Res; 2015 Jun; 32(6):1947-56. PubMed ID: 25471199
[TBL] [Abstract][Full Text] [Related]
18. Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Merz V; Zecchetto C; Santoro R; Simionato F; Sabbadini F; Mangiameli D; Piro G; Cavaliere A; Deiana M; Valenti MT; Bazan D; Fedele V; Lonardi S; Melisi D
Clin Cancer Res; 2020 Sep; 26(17):4661-4669. PubMed ID: 32532788
[TBL] [Abstract][Full Text] [Related]
19. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
20. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors.
Chiang NJ; Chao TY; Hsieh RK; Wang CH; Wang YW; Yeh CG; Chen LT
BMC Cancer; 2016 Nov; 16(1):907. PubMed ID: 27871319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
